Luciano Callegaro

IRCCS Ospedale San Raffaele — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

6h-index2.7kcitations12works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(9), Cytomegalovirus and herpesvirus research(4), CAR-T cell therapy research(4), COVID-19 Clinical Research Studies(2), SARS-CoV-2 and COVID-19 Research(2)

Publications12 total

Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial
Trials·2020· 27 citedOpen Access
Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial.
Research Square (Research Square)·2020Open Access
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Science·2013· 1.0k citedOpen Access
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study
The Lancet Oncology·2009· 481 cited
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
New England Journal of Medicine·2009· 998 citedOpen Access
Long-Term Safety and Efficacy of Gene Therapyfor Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency
Cineca Institutional Research Information System (Tor Vergata University)·2009· 9 cited
Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality
Blood·2008
Clinical improvement and normalized Th1 cytokine profile in early and long‐term interferon‐α treatment in a suspected case of hyper‐IgE syndrome
Pediatric Allergy and Immunology·2008· 5 cited
Antitumor effects of HSV-TK–engineered donor lymphocytes after allogeneic stem-cell transplantation
Blood·2007· 171 citedOpen Access
Long-Term Safety and Efficacy of Stem Cell Gene Therapy for ADA-SCID.
Blood·2006· 1 cited
HSV-TK Engineered Donor Lymphocytes Add-Backs Reduce Late Mortality and Improve Survival of High Risk Acute Leukemia after Haplo-HSCT: Results of a Phase II Multicenter Trial.
Blood·2005· 2 cited
A Phase II Multicenter Trial of HSV-TK Engineered Donor Lymphocytes after Haplo-Identical HSCT: Early Immune Reconstitution and Abrogation of Gvhd.
Blood·2004· 2 cited

Frequent Co-authors

Fabio Ciceri(9), Marco Bregni(9), Claudio Bordignon(8), Alessandro Aiuti(5), Chiara Bonini(5), Attilio Bondanza(5), Monica Salomoni(5), Massimo Bernardi(5), Jacopo Peccatori(5), Alessandra Pescarollo(5), Zulma Magnani(5), Federica Cattaneo(4), Ulrike Benninghoff(4), Massimiliano Mirolo(4), Sarah Marktel(4), Maria Teresa Lupo Stanghellini(4), Scialini Colombi(4), Paolo Servida(4), Serena Perna(4), Fulvio Crippa(4)